LENSAR, Inc. (NASDAQ:LNSR) Short Interest Update

LENSAR, Inc. (NASDAQ:LNSR) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 49,800 shares, a decline of 22.6% from the October 15th total of 64,300 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average trading volume of 31,200 shares, the short-interest ratio is presently 1.6 days.

LENSAR Stock Down 1.7 %

Shares of LNSR traded down $0.12 during mid-day trading on Friday, hitting $7.08. 33,734 shares of the company’s stock were exchanged, compared to its average volume of 42,733. LENSAR has a twelve month low of $2.10 and a twelve month high of $7.95. The firm has a fifty day moving average of $5.28 and a two-hundred day moving average of $4.74. The stock has a market cap of $82.20 million, a price-to-earnings ratio of -4.85 and a beta of 0.59.

Institutional Investors Weigh In On LENSAR

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC acquired a new position in shares of LENSAR in the 2nd quarter worth approximately $93,000. Geode Capital Management LLC increased its holdings in shares of LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after purchasing an additional 3,423 shares in the last quarter. DCF Advisers LLC raised its position in shares of LENSAR by 1.4% during the second quarter. DCF Advisers LLC now owns 241,484 shares of the company’s stock worth $1,087,000 after acquiring an additional 3,250 shares during the last quarter. Finally, Brandes Investment Partners LP boosted its holdings in LENSAR by 12.8% during the second quarter. Brandes Investment Partners LP now owns 373,198 shares of the company’s stock worth $1,644,000 after buying an additional 42,250 shares during the last quarter. 40.15% of the stock is currently owned by institutional investors and hedge funds.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.